Insider Buying: TELA Bio (NASDAQ:TELA) Director Acquires $53,000.00 in Stock

Posted by Brenda Bartman on Sep 19th, 2026

TELA Bio, Inc. (NASDAQ:TELA – Get Free Report) Director Joseph Capper purchased 50,000 shares of the company’s stock in a transaction dated Tuesday, September 15th. The shares were purchased at an average cost of $1.06 per share, for a total transaction of $53,000.00. Following the transaction, the director directly owned 154,827 shares in the company, valued at approximately $164,116.62. This represents a 47.70% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

TELA Bio Stock Down 3.1%

TELA Bio stock opened at $1.25 on Friday. TELA Bio, Inc. has a twelve month low of $0.50 and a twelve month high of $1.69. The business has a fifty day moving average of $0.79 and a two-hundred day moving average of $0.80. The firm has a market cap of $56.42 million, a P/E ratio of -1.62 and a beta of 1.36. The company has a quick ratio of 2.38, a current ratio of 2.99 and a debt-to-equity ratio of 8.82.

TELA Bio (NASDAQ:TELA – Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The business had revenue of $19.29 million for the quarter, compared to analyst estimates of $20.01 million. TELA Bio had a negative return on equity of 1,320.81% and a negative net margin of 51.53%. On average, analysts forecast that TELA Bio, Inc. will post -0.76 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of TELA Bio in a report on Friday, July 17th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, TELA Bio currently has a consensus rating of “Hold” and an average price target of $2.20.

Check Out Our Latest Stock Report on TELA Bio

Institutional Trading of TELA Bio

Several institutional investors and hedge funds have recently bought and sold shares of the business. Nantahala Capital Management LLC acquired a new stake in shares of TELA Bio in the second quarter worth $4,420,586. Stonepine Capital Management LLC acquired a new position in shares of TELA Bio in the 2nd quarter valued at about $1,996,820. Perkins Capital Management Inc. boosted its stake in shares of TELA Bio by 1.5% in the first quarter. Perkins Capital Management Inc. now owns 1,418,328 shares of the company’s stock worth $879,000 after buying an additional 20,910 shares during the last quarter. BlackRock Inc. acquired a new stake in TELA Bio during the second quarter worth about $281,000. Finally, WealthTrust Axiom LLC grew its holdings in TELA Bio by 39.1% during the fourth quarter. WealthTrust Axiom LLC now owns 322,588 shares of the company’s stock worth $381,000 after acquiring an additional 90,650 shares during the period. 94.35% of the stock is currently owned by institutional investors and hedge funds.

TELA Bio Company Profile

(Get Free Report)

TELA Bio, Inc is a medical technology company focused on developing and commercializing implantable products for soft-tissue reconstruction. Its products are designed to support the repair and reinforcement of damaged or weakened soft tissue, including tissue affected by hernias, abdominal wall defects and other reconstructive procedures.

The company’s principal product platform is OviTex Reinforced Tissue Matrix, a family of biologic implants that combines extracellular matrix tissue with a polymer reinforcement structure.